Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer

Vivian Wai Yan Lui, Jennifer Rubin Grandis

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

The incidence of human papillomavirus-positive oropharyngeal cancer (HPV/OPSCC) is rapidly increasing, which will represent a major public health burden for decades to come. Although HPV/OPSCC is generally associated with a better prognosis than HPV-negative OPSCC, the survival rate of individuals with higher-risk clinical and pathologic features remains unchanged. Emerging evidence suggests that HPV/OPSCC is pathologically and molecularly distinct from HPV-negative OPSCC. This review focuses on summarizing treatment strategies for HPV/OPSCC by reviewing the peer-reviewed literature and noting ongoing and planned clinical trials in this disease. We also discuss the potential of designing targeted therapy based on the recent genomic findings of HPV/OPSCC.

Original languageEnglish (US)
Pages (from-to)91-97
Number of pages7
JournalHead and Neck Pathology
Volume6
Issue numberSUPPL. 1
DOIs
StatePublished - 2012
Externally publishedYes

Keywords

  • Chemotherapy
  • HPV/OPSCC
  • Radiation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Otorhinolaryngology
  • Oncology

Fingerprint

Dive into the research topics of 'Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer'. Together they form a unique fingerprint.

Cite this